During the virtual European Hematology Association (EHA) Congress 2021, Valeria Santini, MD, an associate professor of hematology at the University of Florence, in Florence, Italy, discusses the genomic landscape of myelodysplastic syndromes. She discusses research related to the development of a scoring system that integrates the IPSS-R with the molecular and clinical characteristics of MDS. Dr Santini also discusses the impact of mutations, including TP53, on prognosis, and she provides an overview of the role of biomarkers in MDS.